3.58...Immunomedics, Inc.
9:30AM Immunomedics: New data presented from EMBLEM study for pipeline drug Epratuzumab (IMMU) 3.58 +0.14 : UCB and Immunomedics (IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus. Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM, suggest promising results of epratuzumab in patients with SLE.
Market Cap: 270M
Float: 69M
O/S: 75M
Insider own: 8%
Inst. own: 32%
http://www.immunomedics.com/1aboutus/mission.html
Share This Post:
   
In my years of experience, I have come to the conclusion that one useless man is a shame, two is a law firm, and three is a congress. -John Adams (Second president of the United States of America) | |
|
9.18
8.20
